Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure

Clinical Science

Volumn 103, Issue SUPPL. 48, 2002, Pages

  Yamamoto, Takashi ^a   Wada, Atsuyuki ^a   Ohnishi, Masato ^a   Tsutamoto, Takayoshi ^a   Fujii, Masanori ^a   Matsumoto, Takehiro ^a   Takayama, Tomoyuki ^a   Wang, Xinwen ^a   Kurokawa, Kiyoshi ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

CGMP; Endothelin 1; Heart failure; Kidney; Natriuretic peptide; Phosphodiesterase inhibitor

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; ENDOTHELIN 1; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BODY FLUID; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; DOG; DRUG MECHANISM; FLUID BALANCE; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; KIDNEY METABOLISM; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SODIUM EXCRETION; URINE FLOW RATE;

EID: 0036671638     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs103s258s     Document Type: Conference Paper

References (18)

1. Renal endothelin in heart failure and its relation to sodium excretion
2. Renal function, neurohormonal activation, and survival in patients with chronic heart failure
3. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure
4. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors
5. Chronic effects of ANG II antagonist in heart failure: Improvement of cGMP generation from ANP
6. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues
7. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure
8. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
9. Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure
10. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs
11. Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma
12. Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 stain of streptococcus pyogenes
13. Endothelin-1 promotes vascular structural remodeling during the progression of heart failure: Prevention of the vascular remodeling using a specific endothelin-converting-enzyme inhibitor
14. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
15. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
16. Natriuretic peptides inhibit mesangial cell production of endothelin induced by arginine vasopressin
17. Endothelin-1 production by rat inner medullary collecting duct: Effect of nitric oxide, cGMP, and immune cytokines
18. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothetin A receptor antagonism